Maybe already covered by the board...another potential indication for RVX-208 as it attenuates C- reactive protein ? ( Not my field of expertise by any means.)
https://pace-cme.org/2019/09/11/crp-not-only-related-to-recurrent-cv-events-but-also-to-cancer-in-patients-with-stable-
Conclusion
These data show that in patients with stable vascular disease plasma CRP concentration is not only related to risk of recurrent CV events, but also to risk of cancer, in particular lung cancer. This finding supports a role for chronic systemic low-grade inflammation as a stimulating factor in cancer development in patients with established vascular disease.
